Targeting folate receptors to treat invasive urinary bladder cancer

Cancer Research

Volumn 73, Issue 2, 2013, Pages 875-884

  Dhawan, Deepika ^a   Ramos Vara, José A ^b   Naughton, James F ^a   Cheng, Liang ^d   Low, Philip S ^b   Rothenbuhler, Ryan ^a   Leamon, Christopher P ^c   Parker, Nikki ^c   Klein, Patrick J ^c   Vlahov, Iontcho R ^c   Reddy, Joseph A ^c   Koch, Michael ^d   Murphy, Linda ^e   Fourez, Lindsey M ^a   Stewart, Jane C ^a   Knapp, Deborah W ^a,b  

^a PURDUE UNIVERSITY   (United States)

^b PURDUE UNIVERSITY   (United States)

^c Endocyte Inc   (United States)

^d INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EC 0905; FOLATE RECEPTOR; FOLATE VINBLASTINE CONJUGATE; FOLIC ACID; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 343; UNCLASSIFIED DRUG; VINBLASTINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER CANCER; CANCER REGRESSION; CANCER SIZE; CONTROLLED STUDY; DOG; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG RESPONSE; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG METASTASIS; LYMPH NODE METASTASIS; NEUTROPENIA; NONHUMAN; PILOT STUDY; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SCINTIGRAPHY;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, TRANSITIONAL CELL; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; DOGS; FEMALE; FOLATE RECEPTORS, GPI-ANCHORED; FOLIC ACID; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MICE; MICE, NUDE; MIDDLE AGED; PILOT PROJECTS; URINARY BLADDER NEOPLASMS; VINBLASTINE;

EID: 84872551042     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-2101     Document Type: Article

References (39)

1. Tanaka MF, Sonpavde G. Diagnosis and management of urothelial carcinoma of the bladder. Postgrad Med 2011;123: 43-55.
2. Racioppi M, D'Agostino D, Totaro A, Pinto F, Sacco E, D'Addessi A, et al. Value of current chemotherapy and surgery in advanced and metastatic bladder cancer. Urol Int 2012;88: 249-58.
3. Stenzl A, Cowan NC, De Santis M, Kuczyk MA, Merseburger AS, Ribal MJ, et al. Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines. Eur Urol 2011;59: 1009-18.
4. Low PS, Henne WA, Doorneweerd DD. Discovery and development of folic-acid-based receptor targeting for imaging and therapy of cancer and inflammatory diseases. Acc Chem Res 2008;41: 120-9.
5. Zhao X, Li H, Lee RJ. Targeted drug delivery via folate receptors. Expert Opin Drug Deliv 2008;5: 309-19.
6. Parker N, Turk MJ, Westrick E, Lewis JD, Low PS, Leamon CP. Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. Anal Biochem 2005;338: 284-93.
7. Shmeeda H, Mak L, Tzemach D, Astrahan P, Tarshish M, Gabizon A. Intracellular uptake and intracavitary targeting of folate-conjugated liposomes in a mouse lymphoma model with up-regulated folate receptors. Mol Cancer Ther 2006;5: 818-24.
8. Reddy JA, Westrick E, Vlahov I, Howard SJ, SanthapuramHK, Leamon CP. Folate receptor specific anti-tumor activity of folate-mitomycin conjugates. Cancer Chemother Pharmacol 2006;58: 229-36.
9. Reddy JA, Dorton R, Westrick E, Dawson A, Smith T, Xu LC, et al. Preclinical evaluation of EC145, a folate-vinca alkaloid conjugate. Cancer Res 2007;67: 4434-42.
10. Liu Y, Xu S, Teng L, Yung B, Zhu J, Ding H, et al. Synthesis and evaluation of a novel lipophilic folate receptor targeting ligand. Anticancer Res 2011;31: 1521-5.
11. Ye X, Liu Z, Hemida MG, Yang D. Targeted delivery of mutant tolerant anti-coxsackievirus artificial microRNAs using folate conjugated bacteriophage Phi29 pRNA. PLoS ONE 2011;6:e21215.
12. Dosio F, Milla P, Cattel L. EC-145, a folate-targeted vinca alkaloid conjugate for the potential treatment of folate receptor-expressing cancers. Curr Opin Investig Drugs 2010;11: 1424-33.
13. Knapp DW. Animal models: naturally occurring canine urinary bladder cancer. In:Lerner SP, Schoenberg MP, Sternberg CN, editors. Textbook of bladder cancer. Oxon, United Kingdom: Taylor and Francis; 2006. p. 171-5.
14. Rowinsky EK. Antimicrotubule agents. In:Chabner BA, Longo DL, editors. Cancer chemotherapy and biotherapy, practice and principles. Philadelphia, PA: Lipincott Williams and Wilkins; 2006. p. 237-82.
15. Park J, Park S, Song C, Doo C, Cho YM, Ahn H, et al. Effectiveness of adjuvant chemotherapy in transitional cell carcinoma of the urinary bladder with lymph node involvement and/or lymphovascular invasion treated by radical cystectomy. Urology 2007;70: 257-62.
16. Roberts JT, von der Maase H, Sengelov L, Conte PF, Dogliotti L, Oliver T, et al. Long-term survival results of a randomized trial comparing gemcitabine/cisplatin and methotrexate/vinblastine/doxorubicin/cisplatin in patients with locally advanced and metastatic bladder cancer. Ann Oncol 2006;17:Suppl 5:v118-22.
17. Arnold EA, Childress MO, Fourez LM, Tan KM, Stewart JC, Bonney PL, et al. Clinical trial of vinblastine in dogs with transitional cell carcinoma of the urinary bladder. J Vet Intern Med 2011;25: 1385-90.
18. Li J, Sausville EA, Klein PJ, Morgenstern D, Leamon CP, Messmann RA, et al. Clinical pharmacokinetics and exposure-toxicity relationship of a folate-vinca alkaloid conjugate EC145 in cancer patients. J Clin Pharmacol 2009;49: 1467-76.
19. Markert S, Lassmann S, Gabriel B, Klar M, Werner M, Gitsch G, et al. Alpha-folate receptor expression in epithelial ovarian carcinoma and non-neoplastic ovarian tissue. Anticancer Res 2008;28: 3567-72.
20. Kalli KR, Oberg AL, Keeney GL, Christianson TJ, Low PS, Knutson KL, et al. Folate receptor alpha as a tumor target in epithelial ovarian cancer. Gynecol Oncol 2008;108: 619-26.
21. Dhawan D, Craig BA, Cheng L, SnyderPW,MohammedSI, Stewart JC, et al. Effects of short-termcelecoxib treatment in patientswith invasive transitional cell carcinoma of the urinary bladder. Mol Cancer Ther 2010;9: 1371-7.
22. Fisher RE, Siegel BA, Edell SL, Oyesiku NM, Morgenstern DE, Messmann RA, et al. Exploratory study of 99mTc-EC20 imaging for identifying patients with folate receptor-positive solid tumors. J Nucl Med 2008;49: 899-906.
23. Metindir J, Dilek GB, Pak I. Staining characterization by immunohistochemistry of tumor cancer antigen in patients with endometrial cancer. Eur J Gynaecol Oncol 2008;29: 489-492.
24. Charafe-Jauffret E, Tarpin C, Bardou VJ, Bertucci F, Ginestier C, Braud AC, et al. Immunophenotypic analysis of inflammatory breast cancers: identification of an 'inflammatory signature'. J Pathol 2004;202: 265-273.
25. Vlahov IR, Santhapuram HK, You F, Wang Y, Kleindl PJ, Hahn SJ, et al. Carbohydrate-based synthetic approach to control toxicity profiles of folate-drug conjugates. J Org Chem 2010;75: 3685-3691.
26. LeamonCP, Reddy JA, Dorton R, Bloomfield A,Emsweller K, ParkerN, et al. Impact of high and low folate diets on tissue folate receptor levels and antitumor responses toward folate-drug conjugates. J Pharmacol Exp Ther 2008;327: 918-25.
27. Mathias CJ, Wang S, Lee RJ, Waters DJ, Low PS, Green MA. Tumorselective radiopharmaceutical targeting via receptor-mediated endocytosis of Gallium-67-deferoxamine-folate. J Nuc Med 1996;37: 1003-8.
28. Veterinary Co-operative Oncology Group. Veterinary Co-operative Oncology Group- Common Terminology Criteria for Adverse Events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.0. Vet Comp Oncol 2004;2: 194-213.
29. Abbo AH, Jones DR, Masters AR, Stewart JC, Fourez L, Knapp DW. Phase 1 clinical trial and pharmacokinetics of intravesical mitomycin C in dogs with localized transitional cell carcinoma of the urinary bladder. J Vet Intern Med 2010;24: 1124-30.
30. Chun R, Knapp DW, Widmer WR, DeNicola DB, Glickman NW, Kuczek T, et al. Phase II clinical trial of carboplatin in canine transitional cell carcinoma of the urinary bladder. J Vet Intern Med 1997;11: 279-83.
31. Naughton JF, WidmerWR,ConstablePD,KnappDW.Accuracyof threedimensional and two-dimensional ultrasonography for measurement of tumor volume in dogs with transitional cell carcinoma of the urinary bladder. Amer J Vet Res 2012;73: 1919-24.
32. Owen LN. TNMclassification of tumours in domestic animals. Geneva: World Health Organization; 1980.
33. Cheng L, Lopez-Beltran A, Bostwick DG, editors. Bladder pathology. Hoboken, NJ: Wiley-Blackwell; 2012. p. 218-237.
34. Knapp DW. Tumors of the urinary system. In:Withrow SJ, Vail DM, editors. Withrow and MacEwen's small animal clinical oncology. St. Louis, MO: Saunders; 2007. p. 649-58.
35. Henry CJ, McCaw DL, Turnquist SE, Tyler JW, Bravo L, Sheafor S, et al. Clinical evaluation of mitoxantrone and piroxicam in a canine model of human invasive urinary bladder carcinoma. Clin Cancer Res 2003; 9: 906-11.
36. Leamon CP. Folate-targeted drug strategies for the treatment of cancer. Curr Opin Investig Drugs 2008;9: 1277-86.
37. Pribble P, Edelman MJ. EC145: a novel targeted agent for adenocarcinoma of the lung. Expert Opin Investig Drugs 2012;21: 755-61.
38. Sega EI, Low PS. Tumor detection using folate receptor-targeted imaging agents. Cancer Metastasis Rev 2008;27: 655-64.
39. Efstathiou JA, Spiegel DY, Shipley WU, Heney NM, Kaufman DS, Niemierko A, et al. Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience. Eur Urol 2012;61: 705-11.